JP2009543866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543866A5 JP2009543866A5 JP2009520778A JP2009520778A JP2009543866A5 JP 2009543866 A5 JP2009543866 A5 JP 2009543866A5 JP 2009520778 A JP2009520778 A JP 2009520778A JP 2009520778 A JP2009520778 A JP 2009520778A JP 2009543866 A5 JP2009543866 A5 JP 2009543866A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- amount
- pharmaceutical
- formulation
- foamy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 238000009472 formulation Methods 0.000 claims 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims 10
- 239000000194 fatty acid Substances 0.000 claims 10
- 150000004665 fatty acids Chemical class 0.000 claims 10
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 9
- 229960002751 imiquimod Drugs 0.000 claims 9
- 230000002708 enhancing Effects 0.000 claims 5
- 239000003380 propellant Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000003995 emulsifying agent Substances 0.000 claims 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 230000002335 preservative Effects 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 150000002430 hydrocarbons Chemical group 0.000 claims 2
- 208000009621 Actinic Keratosis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 230000002421 anti-septic Effects 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 230000037348 biosynthesis Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000001587 sorbitan monostearate Substances 0.000 claims 1
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 1
- 229940035048 sorbitan monostearate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Claims (39)
- 治療上有効量のイミキモドと脂肪酸とを含む、泡状医薬製剤。
- イミキモドが、前記製剤の全質量に基づき少なくとも1質量％の量で存在する、請求項１記載の泡状医薬製剤。
- イミキモドが、前記製剤の全質量に基づき少なくとも3質量％の量で存在する、請求項１記載の泡状医薬製剤。
- イミキモドが、前記製剤の全質量に基づき少なくとも5質量％の量で存在する、請求項１記載の泡状医薬製剤。
- イミキモドが、前記製剤の全質量に基づき最大6質量％の量で存在する、請求項１記載の泡状医薬製剤。
- 脂肪酸が、前記製剤の全質量に基づき少なくとも5質量％の量で存在する、請求項１〜５のいずれか１項記載の泡状医薬製剤。
- 脂肪酸が、前記製剤の全質量に基づき少なくとも20質量％の量で存在する、請求項１〜６のいずれか１項記載の泡状医薬製剤。
- 脂肪酸が、前記製剤の全質量に基づき最大30質量％の量で存在する、請求項１〜７のいずれか１項記載の泡状医薬製剤。
- 脂肪酸がイソステアリン酸、オレイン酸およびそれらの混合物からなる群より選択される、請求項１〜８のいずれか１項記載の泡状医薬製剤。
- 脂肪酸がイソステアリン酸である、請求項９記載の泡状医薬製剤。
- 噴霧剤をさらに含む、請求項１〜１０のいずれか１項記載の泡状医薬製剤。
- 噴霧剤が、前記製剤の全質量に基づき少なくとも5質量％の量で存在する、請求項１１記載の泡状医薬製剤。
- 噴霧剤が、前記製剤の全質量に基づき少なくとも10質量％の量で存在する、請求項１１記載の泡状医薬製剤。
- 噴霧剤が、前記製剤の全質量に基づき少なくとも15質量％の量で存在する、請求項１１記載の泡状医薬製剤。
- 噴霧剤が炭化水素である、請求項１１〜１４のいずれか１項記載の泡状医薬製剤。
- 炭化水素がプロパン、ブタンおよびそれらの混合物からなる群より選択される、請求項１５記載の泡状医薬製剤。
- 水をさらに含む、請求項１〜１６のいずれか１項記載の泡状医薬製剤。
- 防腐系をさらに含む、請求項１〜１７のいずれか１項記載の泡状医薬製剤。
- 防腐系が、前記製剤の全質量に基づき少なくとも0.1質量％の量で存在する、請求項１８記載の泡状医薬製剤。
- 防腐系が、前記製剤の全質量に基づき最大3質量％の量で存在する、請求項１７記載の泡状医薬製剤。
- 防腐系がメチルパラベン、プロピルパラベン、ベンジルアルコールまたはそれらの混合物を含む、請求項１８〜２０のいずれか１項記載の泡状医薬製剤。
- 乳化剤をさらに含む、請求項１〜２１のいずれか１項記載の泡状医薬製剤。
- 乳化剤が、前記製剤の全質量に基づき少なくとも0.5質量％の量で存在する、請求項２２記載の泡状医薬製剤。
- 乳化剤が、前記製剤の全質量に基づき最大5質量％の量で存在する、請求項２２記載の泡状医薬製剤。
- 乳化剤がポリソルベート60、ソルビタンモノステアレートおよびそれらの混合物からなる群より選択される、請求項２２〜２４のいずれか１項記載の泡状医薬製剤。
- 粘度増強剤をさらに含む、請求項１〜２５のいずれか１項記載の泡状医薬製剤。
- 粘度増強剤が、前記製剤の全質量に基づき少なくとも0.5質量％の量で存在する、請求項２６記載の泡状医薬製剤。
- 粘度増強剤が、前記製剤の全質量に基づき少なくとも1質量％の量で存在する、請求項２６記載の泡状医薬製剤。
- 粘度増強剤が、前記製剤の全質量に基づき最大6質量％の量で存在する、請求項２６記載の泡状医薬製剤。
- 粘度増強剤がセチルアルコール、ステアリルアルコール、キタンサンガムおよびそれらの混合物からなる群より選択される、請求項２６〜２９のいずれか１項記載の泡状医薬製剤。
- 皮膚軟化剤をさらに含む、請求項１〜３０のいずれか１項記載の泡状医薬製剤。
- 湿潤剤をさらに含む、請求項１〜３１のいずれか１項記載の泡状医薬製剤。
- 前記製剤が水中油型乳剤である、請求項１７〜３２のいずれか１項記載の泡状医薬製剤。
- エーロゾルバイアル内に封入された請求項１〜３３のいずれか１項記載の製剤を含む、包装製剤。
- エーロゾルバイアルが絞り弁を備えている、請求項３４記載の包装製剤。
- 光線性角化症を治療するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物。
- 基底細胞癌を治療するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物。
- 肛門生殖器疣贅を治療するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物。
- インターフェロンの生合成を誘導するための医薬組成物であって、治療上有効量のイミキモドと脂肪酸とを含むことを特徴とする医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80766906P | 2006-07-18 | 2006-07-18 | |
| PCT/US2007/016029 WO2008010963A2 (en) | 2006-07-18 | 2007-07-12 | Immune response modifier formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543866A JP2009543866A (ja) | 2009-12-10 |
| JP2009543866A5 true JP2009543866A5 (ja) | 2010-09-02 |
Family
ID=38828444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520778A Pending JP2009543866A (ja) | 2006-07-18 | 2007-07-12 | 免疫応答修飾製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100092401A1 (ja) |
| EP (1) | EP1889609B1 (ja) |
| JP (1) | JP2009543866A (ja) |
| AR (1) | AR062000A1 (ja) |
| AU (1) | AU2007275815A1 (ja) |
| CA (1) | CA2658031C (ja) |
| CL (1) | CL2007002095A1 (ja) |
| IL (1) | IL184563A (ja) |
| ME (1) | MEP18208A (ja) |
| NO (1) | NO343857B1 (ja) |
| RS (1) | RS54276B1 (ja) |
| RU (1) | RU2481108C2 (ja) |
| UA (1) | UA96124C2 (ja) |
| UY (1) | UY30495A1 (ja) |
| WO (1) | WO2008010963A2 (ja) |
| ZA (1) | ZA200901084B (ja) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| NZ540166A (en) | 2002-10-25 | 2007-06-29 | Foamix Ltd | Cosmetic and pharmaceutical foam |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| BRPI0608011A2 (pt) | 2005-03-14 | 2009-11-03 | Graceway Pharmaceuticals Llc | uso de uma formulação para o tratamento da queratose actìnica e uso de 2-metil-1-(2-metilpropil)-1h-imidazo[4,5-c][1,5] naftiridin-4-amina |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
| WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US8501734B2 (en) | 2008-05-26 | 2013-08-06 | Oncotyrol-Center For Personalized Cancer Medicine Gmbh (Ltd.) | Medical intervention in haematological cancers |
| US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| DK2378876T3 (en) | 2008-12-19 | 2019-03-11 | Medicis Pharmaceutical Corp | IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS |
| EP2413876B1 (en) * | 2009-04-01 | 2017-10-04 | MEDA Pharma S.à.r.l. | A multidose package, for delivering predetermined multiple doses of a pharmaceutical |
| US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
| MX336923B (es) | 2009-07-13 | 2016-02-05 | Medicis Pharmaceutical Corp | Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales. |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| AU2011270724B2 (en) * | 2010-06-25 | 2016-10-06 | Medicis Pharmaceutical Corporation | Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis |
| CN107308163A (zh) * | 2010-11-04 | 2017-11-03 | 442合资有限责任公司 | 用于治疗皮肤病的组合物和方法 |
| MX2017011630A (es) | 2016-09-08 | 2018-09-25 | Foamix Pharmaceuticals Ltd | Composiciones y metodos para tratar rosacea y acne. |
| KR101996538B1 (ko) * | 2017-02-13 | 2019-07-04 | 단디바이오사이언스 주식회사 | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US24906A (en) * | 1859-07-26 | Simeon goodfellow | ||
| US3700674A (en) * | 1969-04-30 | 1972-10-24 | American Cyanamid Co | 4-alkylamino-3-nitroquinolines |
| US4013665A (en) * | 1973-10-01 | 1977-03-22 | Bristol-Myers Company | Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines |
| US4052393A (en) * | 1975-11-03 | 1977-10-04 | E. R. Squibb & Sons, Inc. | 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters |
| US4191767A (en) * | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines |
| US4197403A (en) * | 1977-01-07 | 1980-04-08 | Westwood Pharmaceuticals Inc. | 4-Aminosubstituted imidazo(1,2-A)quinoxalines |
| US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
| US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
| ZA848968B (en) * | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
| US4751087A (en) * | 1985-04-19 | 1988-06-14 | Riker Laboratories, Inc. | Transdermal nitroglycerin delivery system |
| US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
| US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| IL92537A (en) * | 1988-12-15 | 1994-04-12 | Riker Laboratories Inc | Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine |
| KR100321649B1 (ko) * | 1993-03-17 | 2002-07-22 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제 |
| CZ294563B6 (cs) * | 1996-10-25 | 2005-02-16 | Minnesota Mining And Manufacturing Company | Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených |
| US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| SI1512685T1 (sl) * | 1997-12-11 | 2006-12-31 | Minnesota Mining & Mfg | Imidazonaftiridini in njihova uporaba v induciranju biosinteze citokina |
| UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| CN1555264A (zh) * | 1999-01-08 | 2004-12-15 | 3M | 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂 |
| DE19941509A1 (de) * | 1999-08-31 | 2001-03-29 | Interconnectron Ges Fuer Ind S | Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen |
| JP4394775B2 (ja) * | 1999-09-03 | 2010-01-06 | 株式会社ダイゾー | 油中水型泡状エアゾール組成物およびその製造方法 |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| WO2003045391A1 (en) * | 2001-11-29 | 2003-06-05 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
| US20060088542A1 (en) * | 2002-03-19 | 2006-04-27 | Powdermed Limited | Imidazoquinoline adjuvants for vaccines |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9668972B2 (en) * | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US20060183767A1 (en) * | 2003-01-06 | 2006-08-17 | Eugene Mandrea | Methods of stimulating immune response in certain individuals |
| NZ567227A (en) * | 2003-03-13 | 2010-01-29 | 3M Innovative Properties Co | Methods of improving skin quality through topical application of an immune response modifier such as imiquimod |
| US7186416B2 (en) * | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
| US20060216333A1 (en) * | 2003-09-02 | 2006-09-28 | Miller Richard L | Methods related to the treatment of mucosal associated conditions |
| US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
| US20050201959A1 (en) * | 2004-03-11 | 2005-09-15 | Vvii Newco 2003, Inc. | Methods and compositions for altering skin coloration |
| US8080560B2 (en) * | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| MX2009000507A (es) * | 2006-07-14 | 2009-06-12 | Stiefel Res Australia Pty Ltd | Espuma farmaceutica de acidos grasos. |
-
2007
- 2007-07-12 NO NO20073601A patent/NO343857B1/no not_active IP Right Cessation
- 2007-07-12 AU AU2007275815A patent/AU2007275815A1/en not_active Abandoned
- 2007-07-12 JP JP2009520778A patent/JP2009543866A/ja active Pending
- 2007-07-12 WO PCT/US2007/016029 patent/WO2008010963A2/en active Application Filing
- 2007-07-12 US US12/309,367 patent/US20100092401A1/en not_active Abandoned
- 2007-07-12 CA CA2658031A patent/CA2658031C/en not_active Expired - Fee Related
- 2007-07-12 IL IL184563A patent/IL184563A/en active IP Right Grant
- 2007-07-12 EP EP07013703.9A patent/EP1889609B1/en active Active
- 2007-07-16 RS RS20070305A patent/RS54276B1/en unknown
- 2007-07-16 ME MEP-182/08A patent/MEP18208A/xx unknown
- 2007-07-17 UA UAA200708131A patent/UA96124C2/ru unknown
- 2007-07-17 RU RU2007127273/15A patent/RU2481108C2/ru active
- 2007-07-18 CL CL2007002095A patent/CL2007002095A1/es unknown
- 2007-07-18 AR ARP070103213A patent/AR062000A1/es unknown
- 2007-07-19 UY UY30495A patent/UY30495A1/es not_active Application Discontinuation
-
2009
- 2009-02-16 ZA ZA200901084A patent/ZA200901084B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543866A5 (ja) | ||
| JP4684404B2 (ja) | 消炎鎮痛外用剤組成物 | |
| ES2391563T5 (es) | Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor | |
| ES2555258T3 (es) | Profármacos de opioides administrables por vía transdérmica, composiciones que no inducen al abuso y procedimientos de uso de los profármacos opioides | |
| RS54276B1 (en) | FOAM FORMULATIONS AS IMMUNE RESPONSE MODIFIERS | |
| JP2008502664A (ja) | カルシトリオールとプロピオン酸クロベタゾールとの組合せ、アルコール相、少なくとも１種の揮発性シリコーン、および１種の不揮発性油性相を含むスプレー組成物 | |
| JP6738120B2 (ja) | 外用医薬組成物 | |
| TW200815045A (en) | Pharmaceutical compositions of ropinirole and methods of use thereof | |
| JP2008513467A5 (ja) | ||
| RU2015143158A (ru) | Композиции для местного применения и способы лечения локальных нарушений | |
| WO2010050889A1 (en) | Topical composition comprising a combination of at least two penetration enhancing agents | |
| RS50025B (sr) | Farmaceutski preparati koji mogu da budu gelirani | |
| NZ600790A (en) | Combination therapy for copd | |
| WO2006100489A2 (en) | A transdermal topical composition and its uses | |
| US20110092438A1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
| EP3677265A1 (en) | Composition for preventing or treating sleep disorders | |
| JP2023168340A (ja) | 末梢神経障害の処置のための局所製剤 | |
| ES2861052T3 (es) | Composición tópica que comprende oxibutinina para el tratamiento de la hiperhidrosis | |
| TWI716394B (zh) | 外用醫藥組合物 | |
| JP5019724B2 (ja) | 抗真菌医薬組成物 | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
| JP2002128701A (ja) | 外用消炎鎮痛剤組成物 | |
| BR112021000183A2 (pt) | preparação medicinal para uso externo | |
| JP2022163191A (ja) | 直腸フォーム製剤 |